NCT05655949 2026-04-22
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
Clinical Trials
7 trialsNCT04339036 2025-12-10
CapTemY90
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05195710 2025-11-10
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05620771 2025-10-20
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Suspended
NCT07070076 2025-08-27
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
First Affiliated Hospital of Jinan University
Phase NA Recruiting
NCT04518748 2025-08-05
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT01349075 2025-04-29
TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
Thomas Jefferson University
Completed